EngineAI Files for Hong Kong IPO Amid Rising Demand for AI and Robotics Stocks 
Hanmi Semicon Shares Surge After $33 Million SpaceX Investment 
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement 
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks 
BHP Port Hedland Workers Back Strike Action Amid Pay Dispute 
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
Roku Explores Sale Options as Interest Grows in Streaming and Ad Business 
Wizz Air Beats Profit Forecast as Cost Controls Offset Industry Challenges 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
Frasers Group Launches €2 Billion Hugo Boss Takeover Offer Amid Control Speculation 
Honda Leadership Crisis Deepens as Retired Executives Challenge CEO Toshihiro Mibe’s Strategy 
OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic 
Meta Partners With Reliance to Launch First AI-Powered Data Center in India 
SpaceX IPO Set for Explosive Debut as Valuation Tops $2.2 Trillion 
Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users 
Woodside Energy Acquires PetroChina’s Browse Stake, Expands Position in Major Australian Gas Project 
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
